Physician profile
Ish Gupta
NPI 1598747834
$2,609.22
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.46 · 2022: $553 · 2023: $972 · 2024: $947 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $617.07 | 2022-2024 | Xarelto |
| Pfizer INC. | $247.49 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $207.21 | 2023-2024 | Airsupra, Lokelma, Breztri |
| Grifols USA, LLC | $148.72 | 2023-2024 | Gamunex-C |
| Amgen INC. | $127.00 | 2024 | Otezla |
| Boston Scientific Corporation | $114.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $113.82 | 2021-2023 | |
| Novo Nordisk INC | $107.10 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.75 | 2022-2025 | Jardiance |
| Abbvie INC. | $106.45 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $100.54 | 2023 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $86.98 | 2025 | Amvuttra |
| Abiomed | $86.20 | 2023-2024 | Impella |
| Neurelis, INC. | $71.51 | 2023-2024 | Valtoco |
| Actelion Pharmaceuticals US, INC. | $64.62 | 2024 | Opsumit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $62.44 | 2024 | |
| Janssen Scientific Affairs, LLC | $56.98 | 2023 | Xarelto |
| Inari Medical, INC. | $55.46 | 2022 | |
| Gilead Sciences, INC. | $46.57 | 2022-2024 | |
| Biomerieux INC | $41.96 | 2023 | Biofire Blood Culture Identification 2 (Bcid2) Panel |
| Lexicon Pharmaceuticals, INC. | $40.34 | 2024 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ish Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.